Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 8/20 | 0.61 |
| ▸ | FNTB | P49356 | 8/20 | 0.61 |
| ▸ | GABRA2 | P47869 | 7/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 7/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5655102 | 0.76 | FNTA (1.00) | FNTAFNTB | |
| SCHEMBL5659913 | 0.76 | FNTA (0.70) | FNTAFNTB | |
| Bromide SCHEMBL5655811 | 0.73 | FNTA (0.53) | FNTAFNTB | |
| SCHEMBL5659809 | 0.71 | FNTA (0.65) | FNTAFNTB | |
| SCHEMBL10729220 | 0.67 | GAA (0.51) | GABRA2GABRB2GAADPP4DPP8 | |
| SCHEMBL5656453 | 0.67 | FNTA (0.59) | FNTAFNTB | |
| SCHEMBL11341455 | 0.67 | GAA (0.56) | GABRA2GABRB2GAADPP4DPP8 | |
| SCHEMBL11354765 | 0.66 | GAA (0.55) | GABRA2GABRB2GAA | |
| SCHEMBL11356784 | 0.66 | GAA (0.57) | GABRA2GABRB2GAADPP4DPP8 | |
| Bromide SCHEMBL11343541 | 0.65 | GAA (0.56) | GABRA2GABRB2GAADPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7173040-B2 | Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derinazoline derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-06 | — | — | US | disclosed |
| US-20040048882-A1 | Farnesyl transferase inhibiting 6-(substituted phenyl) Methy)-quinoline and quinazoline derinazoline derivaties | JANSSEN-CILAG S.A. (FR) | 2004-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048882-A1 | Farnesyl transferase inhibiting 6-(substituted phenyl) Methy)-quinoline and quinazoline derinazoline derivaties | FNTB, FNTA, CYP7A1 | FNTA 2/4885FNTB 1/4885GABRA2 3679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.